Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive To Participate in Piper’s 34th Annual Healthcare Conference
HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be
View HTML
Toggle Summary Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (“Nasdaq”)
View HTML
Toggle Summary Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic Adenocarcinoma Secured Funding to Take the Company Beyond the PROC Readout in Mid-2023 Advanced Development of Batiraxcept in China and Received Significant Milestone
View HTML
Toggle Summary Aravive Announces Approximately $41.5 Million Private Placement Financing
Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors as well as Large Existing Investors HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical-stage oncology company developing targeted therapeutics to
View HTML
Toggle Summary Aravive Receives Third Development Milestone from 3D Medicines
Milestone is Based on 3D Medicines’ Initiation of the Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer in China HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening
View HTML
Toggle Summary Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will
View HTML
Toggle Summary Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will
View HTML
Toggle Summary Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data. Presented Updated Clinical Data at ASCO Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or
View HTML
Toggle Summary Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat
View HTML
Toggle Summary Aravive Appoints Rudy Howard as Chief Financial Officer
HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Rudy Howard as Chief Financial Officer, effective today.
View HTML